Abstract: Methods for the detection or quantitation of amyloid beta include detecting amyloid beta or fragments thereof by mass spectrometry. The methods may also include determining the ratio of amyloid beta 42 (A?42) to amyloid beta 40 (A?40). Such methods may include the diagnosis or prognosis of Alzheimer's disease or dementia.

Abstract: Provided are methods for determining the amount of tamoxifen and its metabolites in a sample by mass spectrometry. In some aspects, the methods provided herein determine the amount of N-Desmethyl Tamoxifen. In some aspects, the methods provided herein determine the amount of N-Desmethyl Tamoxifen and other tamoxifen metabolites. In some aspects, the methods provided herein determine the amount of tamoxifen, N-Desmethyl Tamoxifen, and other tamoxifen metabolites.

Abstract: A method for determining the amount of C peptide in a sample by tandem mass spectrometry includes (a) subjecting a sample suspected of containing C peptide to solid phase extraction to obtain a fraction enriched in C peptide; (b) subjecting the enriched C peptide to an ionization source under conditions suitable to generate one or more C peptide ions detectable by mass spectrometry; and (c) determining the amount of one or more C peptide ions by tandem mass spectrometry; where the one or more C peptide ions comprise a precursor ion with a mass to charge ratio of 1007.5±0.5 and one or more fragment ions selected from the group of ions with mass to charge ratios consisting of 927.6±0.5, 785.4±0.5, and 646.1±0.5; and the amount of ions determined in (c) is related to the amount of a C peptide in the sample.

Abstract: Provided are methods for determining the apolipoprotein E (ApoE) phenotype in a sample by mass spectrometry; wherein the ApoE allele(s) present in the sample is determined from the identity of the ions detected by mass spectrometry. In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.

Abstract: In one embodiment, a system includes a sensor and an airflow generator coupled to an airflow guide configured to direct airflow from the airflow generator toward and past the sensor. The system includes one or more processors and a non-transitory computer readable storage media embodying instructions coupled to the one or more processors, the one or more processors operable to execute the instructions to acquire data about an operational state of the system, wherein the operational state is related to at least one air contaminant generated by the system; and to control the airflow from the airflow generator based on the data about the operational state of the system.

Abstract: Methods are provided for detecting insulin-like growth factor-I (IGF-I) variant(s) in a sample. Methods provided herein are further directed to using the detected ion or ions to determine the presence of IGF1 variant(s) in the sample.

Abstract: A method for determining the amount of testosterone in each of at least two human samples by a single tandem mass spectrometry assay includes subjecting each of a plurality of human samples to a different derivatizing agent to generate a differently derivatized testosterone in each of the plurality of samples, wherein the derivatization agents comprise hydroxylamine chloride and methoxylamine chloride; combining the plurality of samples to form a multiplex sample; and quantifying the amount of testosterone in each sample by mass spectrometry by measuring the amount of a precursor ion having a mass-to-charge ratio of 304.18±0.5 and/or 318.21±0.5 and measuring the amount of a fragment ion having a mass-to-charge ratio of 112.05±0.5, 124.05±0.5, 126.07±0.5, 138.07±0.5, and/or 152.08±0.5.

Abstract: Methods are described for measuring the amount of C peptide in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying C peptide in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.

Abstract: Methods are provided for determining the amount of an IGF-I and/or IGF-II protein in a sample using high resolution/high accuracy mass spectrometry. The methods generally comprise enriching an IGF-I and/or IGF-II protein in a sample, ionizing an IGF-I and/or IGF-II protein from the sample to generate IGF-I and/or IGF-II protein ions, and determining the amount of IGF-I and/or IGF-II protein ions with high resolution/high accuracy mass spectrometry.

Abstract: Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (A?42) to amyloid beta 40 (A?40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.

Abstract: Provided herein are methods for high throughput quantitation of testosterone utilizing at least two different derivatizing agents of different masses. In another aspect, provided herein are methods for determining the amount of testosterone in each of a plurality of human samples with a single mass spectrometric assay by subjecting each of a plurality of human samples to a different derivatizing agent to generate a differently derivatized testosterone in each of the plurality of samples; combining the plurality of samples to form a multiplex sample; and quantifying the amount of testosterone in each sample by mass spectrometry.

Abstract: A method of determining the amount of an IGF-I and/or IGF-II protein in a sample using high resolution/high accuracy mass spectrometry includes enriching an IGF-I and/or IGF-II protein in a sample, ionizing an IGF-I and/or IGF-II protein from the sample to generate IGF-I and/or IGF-II protein ions, and determining the amount of IGF-I and/or IGF-II protein ions with high resolution/high accuracy mass spectrometry.

Abstract: Provided are methods of detecting the presence or amount of a dihydroxyvitamin D metabolite in a sample using mass spectrometry. The methods generally comprise ionizing a dihydroxyvitamin D metabolite in a sample and detecting the amount of the ion to determine the presence or amount of the vitamin D metabolite in the sample. In certain preferred embodiments the methods include immunopurifying the dihydroxyvitamin D metabolites prior to mass spectrometry. Also provided are methods to detect the presence or amount of two or more dihydroxyvitamin D metabolites in a single assay.

Abstract: In one embodiment, an apparatus includes a controller trigger that includes an input surface configured to receive input based on movement of a finger of a user, the trigger having a range of motion along a trigger path. The apparatus further includes a mode selector configured to actuate movement of an intermediate switching component between a discrete-input mode and a variable-input mode. The intermediate switching component includes a moveable arm, and in the discrete input mode the moveable arm occupies at least a portion of the trigger path, thereby limiting the range of motion of the trigger; and in the variable input mode the moveable arm does not occupy the trigger path. The apparatus further includes a switch configured to receive input, in the discrete-input mode, based on a movement of the intermediate switching component, in response to a physical contact by the trigger.

Abstract: Provided are methods of detecting the presence or amount of a dihydroxyvitamin D metabolite in a sample using mass spectrometry. The methods generally comprise ionizing a dihydorxyvitamin D metabolite in a sample and detecting the amount of the ion to determine the presence or amount of the vitamin D metabolite in the sample. In certain preferred embodiments the methods include immunopurifying the dihydroxyvitamin D metabolites prior to mass spectrometry. Also provided are methods to detect the presence or amount of two or more dihydroxyvitamin D metabolites in a single assay.

Abstract: In one embodiment, an apparatus includes a human-interface-device (HID) controller that includes at least one of an extended reality (XR) controller or a mouse controller. The apparatus further includes an undetachable, fully retractable stylus pointed tip configured to extend from the HID controller, configured so that the stylus tip does not protrude beyond an exterior of the HID controller when in a fully retracted position.

Abstract: In one embodiment, an apparatus includes a human-interface-device (HID) controller that includes at least one of an extended reality (XR) controller or a mouse controller. The apparatus further includes an undetachable, fully retractable stylus pointed tip configured to extend from the HID controller, configured so that the stylus tip does not protrude beyond an exterior of the HID controller when in a fully retracted position.

Abstract: Various examples are provided related to methane detection in harsh environments. In one example, a method includes drawing a sample of air from at least one first location; delivering the sample to a volume within a sensor block at a second location, where the sensor block includes a gas concentration sensor in communication with the volume; and where a vacuum is applied to the volume within the sensor block to facilitate delivery of the sample to the second location. In another example, a system includes a sampling unit that houses a sensor block, where a sample tube is coupled to an inlet of the sensor block, which includes a gas concentration sensor; an ejector that facilitates delivery of a sample of air from the first location via the sample tube; and a control unit that can receive a gas concentration sensor output from the sampling unit for processing.

Abstract: Provided are methods for determining the apolipoprotein E (ApoE) phenotype in a sample by mass spectrometry; wherein the ApoE allele(s) present in the sample is determined from the identity of the ions detected by mass spectrometry. In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.

Abstract: In one embodiment, a method includes accessing a temperature map of a food item in a cooking apparatus, where the temperature map comprises a plurality of regions of the food item and associates a temperature with each region, and the cooking apparatus cooks according to an initial heating technique. The method includes determining, by a computing device, whether a temperature associated with at least one region of the food item violates a predetermined temperature constraint, and in response to a determination that the temperature associated with at least one region of the food item violates a predetermined temperature constraint, then determining an optimal heating technique and instructing the cooking apparatus to cook according to the optimal heating technique. In response to a determination that the temperature of each region does not violate a predetermined temperature constraint, the method includes determining that the initial heating technique should not be changed.